

RVC OPEN ACCESS REPOSITORY – COPYRIGHT NOTICE

This author's accepted manuscript may be used for non-commercial purposes in accordance with [Wiley Terms and Conditions for Self-Archiving](#).

The full details of the published version of the article are as follows:

TITLE: CLINICAL AND MAGNETIC RESONANCE IMAGING FEATURES OF IDIOPATHIC OCULOMOTOR NEUROPATHY IN 14 DOGS

AUTHORS: Roser Tetas Pont, Courtenay Freeman, Ruth Dennis, Claudia Hartley, Elsa Beltran

JOURNAL: VETERINARY RADIOLOGY & ULTRASOUND

PUBLISHER: Wiley

PUBLICATION DATE: May/June 2017

DOI: [10.1111/vru.12478](https://doi.org/10.1111/vru.12478)

1 **Title**

2 CLINICAL AND MAGNETIC RESONANCE IMAGING FEATURES OF
3 IDIOPATHIC OCULOMOTOR NEUROPATHY IN 14 DOGS

4 **Authors**

5 Roser Tetas Pont. Comparative Ophthalmology Unit, Animal Health Trust, Lanwades
6 Park, Kentford CB8 7UU United Kingdom. Current address: Queen Mother Hospital for
7 Animals. Royal Veterinary College. Hawkshead Lane, North Mymms, Hertfordshire AL9
8 7TA United Kingdom. rtetas@rvc.ac.uk

9

10 Courtenay Freeman. Neurology/Neurosurgery Unit, Animal Health Trust, Lanwades
11 Park, Kentford CB8 7UU United Kingdom. Current address: Veterinary Specialty Care,
12 985 Johnnie Dodds Blvd, Mount Pleasant, SC 29464.
13 cfreeman@veterinaryspecialtycare.com

14

15 Ruth Dennis. Diagnostic Imaging Unit, Animal Health Trust, Lanwades Park, Kentford
16 CB8 7UU United Kingdom. ruth.dennis@aht.org.uk

17

18 Claudia Hartley. Comparative Ophthalmology Unit, Animal Health Trust, Lanwades
19 Park, Kentford CB8 7UU United Kingdom. Current address: Davies Veterinary
20 Specialists, Manor Farm Business Park, Higham Gobion, Herts SG5 3HR United
21 Kingdom. chartley@vetspecialists.co.uk

22

23 Elsa Beltran. Neurology/Neurosurgery Unit, Animal Health Trust, Lanwades Park,
24 Kentford CB8 7UU United Kingdom. Current address: Queen Mother Hospital for
25 Animals. Royal Veterinary College. Hawkshead Lane, North Mymms, Hertfordshire AL9
26 7TA United Kingdom. ebeltran@rvc.ac.uk

27

28 **Corresponding address**

29 Roser Tetas Pont

30 rtetas@rvc.ac.uk

31

32 **Key Words**

33 canine, ophthalmoplegia, oculomotor nerve, MRI, CNIII

34

35 **Running head**

36 Canine idiopathic oculomotor neuropathy

37

38

39

40

41

42

43

44

45

46 **Abstract**

47 Ophthalmoplegia/ophthalmoparesis (internal, external, or both) has been reported in dogs
48 secondary to neoplasia affecting the oculomotor nerve and is usually given a poor
49 prognosis. The purpose of this retrospective study was to describe the clinical findings,
50 magnetic resonance imaging (MRI), management, outcome and follow-up of canine cases
51 with idiopathic oculomotor neuropathy. Inclusion criteria included cases with
52 ophthalmoplegia/ophthalmoparesis (internal, external or both) as sole neuro-
53 ophthalmologic sign, complete ophthalmic and neurologic examination, head MRI, and a
54 minimum follow-up of one year. Dogs with progressive neurological signs not related
55 with oculomotor neuropathy were excluded. Fourteen cases met the inclusion criteria. All
56 cases were unilaterally affected. Magnetic resonance imaging showed equivocal
57 enlargement of the oculomotor nerve in three cases, mild enlargement in five and marked
58 enlargement in six. Contrast enhancement was present in twelve cases, being marked in
59 six. When present, the contrast enhancement was focal in eight cases and diffuse in four.
60 The median follow-up time was 25 months. External ophthalmoparesis improved in
61 seven cases, five cases under no treatment and two under systemic corticosteroid therapy.
62 The clinical signs in the other seven cases remained unchanged. Idiopathic oculomotor
63 neuropathy should be included as a differential diagnosis in dogs presenting with
64 unilateral ophthalmoplegia/ophthalmoparesis (internal, external, or both) with the
65 absence of other neurologic and ophthalmic signs, and with the MRI findings restricted to
66 the oculomotor nerve. Idiopathic oculomotor neuropathy has a good prognosis as the
67 clinical signs do not deteriorate and they can improve without treatment.

68

69 **Introduction**

70 The oculomotor nerve (cranial nerve III or CN III) innervates the ipsilateral extraocular
71 muscles (dorsal, ventral, and medial rectus and ventral oblique muscle) and the ipsilateral
72 levator palpebrae superioris muscle.¹ Additionally, CN III controls ipsilateral pupillary
73 constriction through its parasympathetic component.¹ A complete CN III lesion (motor
74 and parasympathetic dysfunction) causes areflexive mydriasis (internal ophthalmoplegia),
75 a smaller palpebral fissure due to ptosis, neuromuscular dorsolateral strabismus, and the
76 affected eye will not adduct well on testing physiological nystagmus (vestibulo-ocular
77 reflex) (external ophthalmoparesis).² In the veterinary literature, canine
78 ophthalmoplegia/ophthalmoparesis (internal, external, or both) has been reported
79 secondary to neoplasia affecting CN III at the level of the middle cranial fossa (MCF) or
80 orbital fissure,³⁻¹² and it is usually given a poor prognosis.² Idiopathic trigeminal and
81 facial neuropathy have been reported in dogs;¹³⁻¹⁷ however, idiopathic oculomotor
82 neuropathy is currently not reported in the veterinary literature. The aims of this study
83 were to describe the clinical findings, magnetic resonance imaging (MRI) features,
84 management, outcome, and long-term follow-up of canine cases diagnosed with
85 idiopathic oculomotor neuropathy.

86

87 **Methods**

88 Medical records of all dogs referred to the Animal Health Trust for
89 ophthalmoplegia/ophthalmoparesis from January 1999 to December 2014 were reviewed.
90 Inclusion criteria included all cases with ophthalmoplegia/ophthalmoparesis (internal,
91 external or both) as sole neuro-ophthalmologic sign, complete ophthalmic and neurologic

92 examination, head MRI, and a minimum follow-up of one year. Dogs with progressive
93 neurological signs not related to oculomotor neuropathy were excluded.

94 Patient information collected included the following: age, gender, breed, duration of
95 clinical signs prior to referral, clinical signs and affected side at presentation, MRI
96 findings, cerebrospinal fluid (CSF) analysis, treatment, and follow-up. All MRI studies
97 were reviewed by a board-certified veterinary neurologist (E.B.) and a board-certified
98 veterinary radiologist (R.D.), who were unaware of the side of the clinical signs.

99 Disagreement was resolved by a consensus reading by the two reviewers. Five MRI
100 parameters were evaluated in each case and included the following: (1) enlargement of
101 CN III (equivocal, mild or marked), (2) intensity at the area of CN III on T2W and T1W
102 and also on FLAIR when available (hypointense, isointense or hyperintense), (3) post-
103 contrast enhancement at the area of CN III (none, mild or marked), (4) features of post-
104 contrast enhancement at the area of CN III (focal or diffuse enhancement and
105 homogenous or heterogeneous enhancement), and (5) anatomical region of the lesion.

106 The enlargement was classified as equivocal when there was uncertainty about the
107 presence or absence of enlargement, mild when the affected CN III was enlarged
108 compared to the contralateral but there was no mass effect to the surrounding neuropil,
109 and marked when the affected CN III was enlarged and there was mass effect to the
110 surrounding neuropil. The intensity of CN III on T2W was classified as hypointense
111 when its brightness was inferior to the brightness of normal gray matter, isointense when
112 its brightness was equal to the normal gray matter, and hyperintense when its brightness
113 was superior to the brightness of normal gray matter. This was repeated for T1W and also
114 for FLAIR when available. The post-contrast enhancement was categorized as mild when

115 there was contrast enhancement that was hypointense compared to the fat tissue on T1W
116 images, and marked when the contrast enhancement was isointense to the fat tissue on
117 T1W images. The contrast enhancement was classified as diffuse when detected
118 throughout the length of CN III and focal when only present at a focal location of CN III.
119 And finally, the contrast enhancement was categorized as homogenous when there was
120 uniform enhancement and heterogeneous when it was dissimilar throughout the enhanced
121 area. If follow-up MRI was available, the images were evaluated following the same
122 parameters.

123 For each patient, long term follow-up was performed with a combination of clinical re-
124 examinations, evaluation of the clinical records post-diagnosis and phone conversation
125 with the owner. The referring veterinarians were contacted for the clinical history post-
126 diagnosis of the patients. The owners whose dogs were alive at the start of the study were
127 invited for a re-examination at the Animal Health Trust. Cases re-examined received a
128 complete ophthalmic examination by a European College of Veterinary Ophthalmologists
129 trained ophthalmologist (R.T.P.) and neurological examination by board-certified
130 veterinary neurologists (C.F. and E.B.). In cases of dogs either lost to follow-up, dead or
131 not available for re-examination, the long-term follow-up was determined based on the
132 clinical records post-diagnosis and the phone conversation with the owner.

133

134 **Results**

135 *Signalment and Clinical Findings*

136 Fourteen cases met the inclusion criteria (Appendix 1). The mean (standard deviation,
137 SD) and median (range) age at presentation were 6.25 years (2.3) years and 6.5 years (3

138 to 10 years), respectively. There were entire females (n = 1, 7%), neutered females (n = 7,
139 50%), entire males (n = 2, 14%), and neutered males (n = 4, 29%). The distribution of the
140 individual breeds is shown in Appendix 1, with the more commonly affected breeds
141 being Boxer (n = 4, 29%) and Border Collie (n = 2, 14%). The mean (SD) and median
142 (range) duration of the clinical signs prior to referral were 73 days (195) and 5 days (1
143 day to 2 years), respectively. Cases presented with both internal and external
144 ophthalmoplegia/ophthalmoparesis (n = 11, 79%, Fig 1.) or only internal
145 ophthalmoplegia (n = 3, 21%). The clinical signs were unilateral in all cases, being right
146 sided (n = 8, 57%) or left sided (n = 6, 43%).

147

148 *Magnetic Resonance Imaging Findings*

149 Magnetic resonance of the head was performed using a 1.5T scanner (GE Signa, GE
150 Medical System, Milwaukee, WI, USA). Non-contiguous transverse images with a 3-5-
151 mm slice thickness and an interslice gap of 0.3-0.5 mm were generated with T1-weighted
152 (T1W) and T2-weighted (T2W) spin echo pulse sequences in all three planes. Sequences
153 included T1W and T2W and T1W with fat saturation (FAT-SAT). T1W FAT-SAT
154 images were also acquired after intravenous paramagnetic contrast medium,
155 0.05mmol/kg, gadobenate dimeglumine (Multi-Hance®, Bracco Imaging SpA, Milan
156 Italy). T1W post contrast FAT-SAT and fast fluid-attenuation inversion recovery
157 (FLAIR) findings were recorded when available. Magnetic resonance findings are
158 detailed in Appendix 2. Equivocal enlargement of CN III was noted in three cases (n = 3,
159 21%; Fig. 2), mild enlargement in five cases (n = 5, 35%; Fig. 3) and marked
160 enlargement in six cases (n = 6, 43%; Fig. 4). The affected CN III was isointense on T2W

161 and T1W pre-contrast sequences in five cases (n = 5, 35%; Fig. 2), hyperintense on T2W
162 and isointense on T1W in seven cases (n = 7, 50%; Fig. 3) and hypointense on T2W and
163 isointense on T1W in two cases (n = 2, 14%). FLAIR sequence was available in all cases
164 but in two dogs; the intensity on FLAIR was equal to T2W in all case but three cases, a
165 case with hyperintense CN III on T2W and isointense on FLAIR, and two cases with
166 isointense on T2W and hypointense on FLAIR were noted. Contrast enhancement was
167 present in all but two cases (n = 12, 86%), being marked in six cases (n = 6, 43%). When
168 present, the contrast enhancement was focal in eight cases (n = 8, 67%) and diffuse in the
169 rest (n = 4, 33%). In all cases, the anatomical region of the lesion was at the level of the
170 middle cranial fossa; however, in some cases with diffuse enhancement, the lesion
171 extended into the orbital fissure (n = 3, 21%).

172

173 *Other findings*

174 Comprehensive haematology and biochemistry were available in 13 cases and were
175 unremarkable in all. Thyroid function was evaluated in three dogs and was determined
176 within normal limits in all cases. One patient (Case 7) had been previously diagnosed
177 with hypothyroidism; however, the dog was receiving thyroid hormone supplementation
178 and the thyroid values were within normal limits at presentation. Thoracic radiographs
179 and abdominal ultrasonography were performed in seven patients and were unremarkable
180 in all. Cerebrospinal fluid was collected from the cerebellomedullary cistern in 13 dogs
181 (Appendix 1). The mean (SD) and median (range) nucleated cell count was 1.99 cells/uL
182 (2.06) and 1 cells/uL (0 to 8 cells/uL), respectively. The nucleated cell count was elevated
183 in two patients (n = 2, 14%), with 6 and 8 cells/uL (reference range 0-5 cells/uL)

184 respectively. The nucleated cellular population consisted in scattered small/medium
185 lymphocytes and monocytes in all cases, apart from Case 14 were the main population of
186 cells were hypersegmented non-degenerated neutrophils. The mean (SD) and median
187 (range) CSF total protein were 0.30 g/L (0.17) and 0.25 g/L (0.19 to 0.80 g/L),
188 respectively. The total protein was elevated in one patient (n = 1, 7%; reference range 0-
189 0.35 g/L; Case 14). Polymerase chain reaction for canine distemper virus, *Toxoplasma*
190 *gondii* and *Neospora caninum* were negative in blood and CSF in all dogs tested (n = 9,
191 64%).

192

193 *Treatment and Follow-up*

194 The treatment and follow-up information is detailed in Appendix 3. Anti-inflammatory to
195 immunosuppressive doses of systemic corticosteroid (prednisolone at 1 mg/kg once to
196 twice daily) was started at presentation in seven dogs (n = 7, 50%). Only two dogs
197 showed improvement of the clinical signs while under systemic corticosteroid treatment
198 (n = 2, 29%; Cases 4 and 14). Case 10 developed severe gastrointestinal side effects
199 within the first week of treatment and the medication was discontinued at that point. The
200 neurological signs in this dog improved three weeks after the systemic corticosteroid
201 treatment was discontinued. Case 9 showed improvement of the clinical signs three
202 months after discontinuation of the systemic corticosteroid treatment. Furthermore, three
203 dogs without systemic corticosteroid treatment (n = 3, 43%; Cases 6, 7 and 12) improved
204 two weeks to four months after their presentation. In the other seven dogs the clinical
205 signs remained unchanged, three received a course of systemic steroid therapy and four
206 had no treatment.

207 Six-month follow-up MRI scan was available in two cases (Cases 8 and 14). In case 8,
208 MRI findings at re-examination remained unchanged compared to presentation and
209 clinical signs were not improved. In case 14, MRI at presentation revealed marked
210 enlargement with marked diffuse post-contrast enhancement; however, at re-examination
211 the follow-up MRI showed equivocal enlargement with no post-contrast enhancement
212 (Fig. 5), and clinical signs were improved at that time.

213 The mean (SD) and median (range) long-term follow-up time was 33.93 months (21.76)
214 and 25 months (12 to 84 months), respectively. The external ophthalmoparesis improved
215 in 64% cases (7/11 dogs) during this period of time and the neuromuscular strabismus
216 resolved. The internal ophthalmoplegia/ophthalmoparesis remained unchanged in 79%
217 cases (11/14 dogs) and partially resolved in 21% cases (3/14 dogs). The mean (SD) and
218 median (range) time to improvement was 5.55 weeks (5.53) and 3.57 weeks (11 days to 4
219 months) respectively, from the day the clinical signs were first noted. Follow-up of over
220 one year with complete ophthalmic and neurological re-examination by the authors was
221 possible in six cases.

222

223 **Discussion**

224 This is the first descriptive study of idiopathic oculomotor neuropathy in dogs. The
225 presumptive diagnosis of idiopathic neuropathy was made in all cases based on the failure
226 on revealing an underlying cause. A putative association between cranial neuropathy and
227 hypothyroidism has been stated in the veterinary literature,^{18,19} however this is not borne
228 out by other studies.^{17,20} None of the dogs of this study showed clinical signs of
229 hypothyroidism and the thyroidal function was normal in the three dogs tested. One case

230 had been previously diagnosed with hypothyroidism; however, the authors think that
231 there is unlikely association between the hypothyroidism and the oculomotor neuropathy
232 due to the fact that at the time of the onset of the clinical signs (oculomotor neuropathy)
233 the dog did not reveal any clinical signs consistent with hypothyroidism and the thyroid
234 function was controlled. Infectious causes of neuropathy are exceptionally rare in dogs,²
235 and none of the dogs tested in this report for canine distemper virus, *Toxoplasma gondii*
236 and *Neospora caninum* were positive. In this study, the lack of clinical deterioration in all
237 cases and the clinical improvement in several dogs might indicate the presence of an
238 underlying oculomotor neuritis with subsequent permanent nerve damage. Furthermore,
239 the MRI findings (CN III enlargement with contrast enhancement) and the mildly
240 elevated cell count in CSF (in two dogs) could support this hypothesis. However, this
241 hypothesis could not be confirmed due to the lack of histopathology and for this reason
242 the term idiopathic neuropathy was adopted. Surgical biopsy at this area carries high
243 operative morbidity due to the location and to the authors' knowledge this surgical
244 approach has not been attempted in dogs.

245 All cases in this study presented with mydriasis, and only two dogs retained some
246 pupillary response to light at presentation. On the other hand, external ophthalmoparesis
247 was only seen in some dogs. The oculomotor parasympathetic axons are located
248 superficially on the medial side of CN III,¹ subsequently if the neuropathy initiates in this
249 location it is likely that only the parasympathetic component will be affected. The clinical
250 signs were unilateral in all dogs in this study, similar to the reported canine cases of
251 idiopathic facial neuropathy but different to trigeminal neuropathy.¹³⁻¹⁷ There are several
252 cases published of unilateral idiopathic trigeminal neuropathy in dogs,²¹ however the

253 majority are bilaterally affected.¹³ Bilateral trigeminal neuropathy commonly presents
254 with sudden inability to close the mouth;¹³ on the other hand, unilateral trigeminal
255 neuropathy may only manifest with unilateral transitory masticatory muscle atrophy.²
256 Subsequently, it is possible that unilateral cases of trigeminal neuropathy of the
257 mandibular branch are overlooked by owners and veterinarians if the atrophy is mild or
258 transitory. The mean recovery time of motor function was five weeks in the present
259 study, similar to other idiopathic cranial neuropathies;^{13,14,16} however, a third of the cases
260 affected with CN III motor dysfunction (4/11 dogs) in our study showed no signs of
261 improvement. This finding differs from trigeminal neuropathy where the motor function
262 recovered in all cases;¹³ but similar to facial neuropathy, where resolution of clinical
263 signs was only seen in half of the affected dogs.^{14,15,16} Some degree of mydriasis persisted
264 in all cases in our study; however, almost a quarter of patients recovered partial CN III
265 parasympathetic function. Medical treatment with corticosteroids did not appear to alter
266 the course of the disease in this study, even though the dose used and length of course
267 varied. Further studies are required to prove the efficacy of corticosteroids for the
268 treatment of idiopathic oculomotor neuropathy, however corticosteroid therapy does not
269 appear to change the clinical outcome of other cranial neuropathies.^{13,22}
270 A total of 22 cases of canine ophthalmoplegia/ophthalmoparesis (internal, external or
271 both) are published in the veterinary literature.³⁻¹² Of these 22 cases, only three report
272 isolated CN III deficits,^{5,8,10} the rest of the reports describe dogs with multiple cranial
273 nerve dysfunction as part of middle cranial fossa syndrome (also known as cavernous
274 sinus syndrome) or other neurological signs.^{3-7,9,11,12} The middle cranial fossa is a paired
275 depression of the basiphenoid bone, located between the rostral and caudal cranial fossa

276 at the base of the skull.¹ Multiple cranial nerves travel through the middle cranial fossa
277 including the oculomotor, trochlear and abducens nerves, as well as the three branches of
278 the trigeminal nerve.¹ These cranial nerves exit/enter the skull through the orbital fissure
279 (oculomotor nerve, trochlear nerve, abducens nerve and ophthalmic branch of the
280 trigeminal nerve), round foramen (maxillary branch of the trigeminal nerve), or oval
281 foramen (mandibular branch of the trigeminal nerve).¹ The middle cranial fossa
282 syndrome is a well-recognised syndrome in dogs characterised by variable impairment of
283 these nerves.² In the veterinary literature, this syndrome is usually referred to as
284 cavernous sinus syndrome.^{3,4,6,7,9,10} However, this term should ideally be discarded,
285 because these cranial nerves are not directly related to the cavernous sinus.² Twelve of 22
286 dogs published in the veterinary literature showed unilateral deficits,^{3-8,10-12} two cases
287 presented with unilateral signs and became bilateral within days,^{4,6} and six cases had
288 bilateral deficits at presentation.^{4,5,9} All cases were reported to be secondary to neoplasia
289 at the level of the middle cranial fossa or orbital fissure.³⁻¹² Ten dogs were euthanized at
290 presentation,^{3-5,7,10,12} and for the rest, the mean life expectancy after diagnosis was 7.1
291 months^{3,4,6,8-10} with the longest survival time of 18 months.⁶ Clinical signs deteriorated
292 over this period of time in all cases, precipitating euthanasia.^{3,4,6,8-10} For this reason, the
293 inclusion criteria of the current study demanded a minimal follow-up time of 12 months
294 and only dogs with no deterioration of the neurological signs were included.
295 Magnetic resonance is the diagnostic imaging modality of choice in veterinary medicine
296 for diseases affecting cranial nerves.²³ Magnetic resonance provides superior resolution
297 of the retrobulbar and intracranial CN III pathway compared to computed tomography.²³
298 In this study, MRI enabled an accurate and detailed morphological assessment of the

299 lesions in all cases, only two dogs had equivocal enlargement of the CN III and no post-
300 contrast enhancement on MRI. Localization and extension of the lesions were in
301 accordance with the neuroanatomic localization in all cases, and six months follow-up
302 MRI was possible in two. Based upon the location, shape, invasiveness, signal intensity,
303 homogeneity, and enhancement properties of the lesion, MRI features can help the
304 differentiation between neoplastic and inflammatory disorders in cranial nerves
305 dysfunction.^{21,24,25} Human patients that have cranial nerve enhancement following
306 contrast medium administration, but do not have an associated mass are considered to
307 have cranial neuritis or ganglionitis rather than neoplasia.²⁵ Similarly in veterinary
308 medicine, dogs with trigeminal neuritis confirmed postmortem had diffuse enlargement
309 of the nerve without a mass lesion.²¹ In the present study, six cases had marked
310 enlargement of the CN III with mass effect in the surrounding tissue; three of these had
311 diffuse enhancement in most of the length of the CN III, and the other marked focal
312 enlargement of the nerve that could be considered a neoplastic lesion based on previously
313 published literature. The pathogenesis of the disease in this study remains currently
314 obscure, however, no deterioration of the clinical signs, no involvement of other cranial
315 nerves or general condition was noted in any the dogs with a follow-up time of 20 to 41
316 months, which would be expected with a neoplastic lesion over that length of time.
317 Therefore, we could conclude that idiopathic oculomotor neuropathy is not indicative of a
318 serious underlying disorder.

319 The main limitations of this study include the low number of cases, lack of pathologic
320 confirmation, lack of standardized MRI protocols and heterogeneous nature of the study
321 design. Results could be more definitively supported with a prospective multi-center

322 study. Futures studies could also evaluate the sensitivity and specificity of MRI for
323 detecting CN III abnormalities in dogs with idiopathic oculomotor neuropathy. Moreover,
324 MRI features (including a more objective measurement for cranial nerve enlargement)
325 could be evaluated as prognostic factors for regaining full CN III function. The lack of
326 histopathology was unavoidable due to the non-fatal nature of this condition and the high
327 morbidity that a surgical biopsy could carry due to the location of the lesion. The authors
328 applied stringent inclusion criteria for sampled animals in the current study in order to
329 maximize the likelihood of a true positive diagnosis as much as possible.

330

331 In conclusion, findings from the current study supported including idiopathic oculomotor
332 neuropathy as a differential diagnosis for dogs presenting with unilateral
333 ophthalmoplegia/ophthalmoparesis (internal, external, or both) with the absence of other
334 neurological and ophthalmic signs, and with MRI lesions restricted to CN III. These cases
335 can have a good prognosis as the clinical signs do not deteriorate or can even improve
336 without treatment.

337

338 **List of Author Contributions**

339 Category 1

340 (a) Conception and Design: Elsa Beltran, Roser Tetas Pont and Courtenay Freeman

341 (b) Acquisition of Data: Roser Tetas Pont, Courtenay Freeman and Elsa Beltran

342 (c) Analysis and Interpretation of Data: Roser Tetas Pont, Courtenay Freeman, Elsa
343 Beltran, Ruth Dennis and Claudia Hartley

344 Category 2

345 (a) Drafting the Article: Roser Tetas Pont, Elsa Beltran and Courtenay Freeman

346 (b) Revising Article for Intellectual Content: Roser Tetas Pont, Elsa Beltran,

347 Courtenay Freeman, Claudia Hartley and Ruth Dennis

348 Category 3

349 (a) Final Approval of the Completed Article: Roser Tetas Pont, Courtenay Freeman,

350 Claudia Hartley, Ruth Dennis and Elsa Beltran

351

352 **Acknowledgments**

353 To our colleagues and referring veterinary surgeons for their support, and providing the

354 contact details of their clients and the clinical histories of their patients.

355 **References**

356 1. Evans HE, De Lahunta A. Cranial nerves (Chapter 18) in: Miller's anatomy of the

357 dog, 4th ed. Missouri: Saunders Elsevier 2013;708-730.

358 2. De Lahunta A, Glass E, Kent M. Lower motor neurone: General visceral efferent

359 system (Chapter 7) in: Veterinary neuronatomy and clinical neurology, 4th ed.

360 Missouri: Saunders Elsevier 2015;162-180.

361 3. Lee R, Griffiths IR. A comparison of cerebral arteriography and cavernous sinus

362 venography in the dog. J Small Anim Pract 1972;5:225-238.

363 4. Lewis GR, Blanchard GL, Trapp AL. Ophthalmoplegia caused by thyroid

364 adenocarcinoma invasión of the cavernous sinus in the dog. J Am Anim Hosp

365 Assoc 1984;20:805-812.

- 366 5. Valentine BA, Summers BA, de Lahunta A, White CL, Kuhajda FP. Suprasellar
367 germ cell tumors in the dog: a report of five cases and review of the literature.
368 *Acta Neuropathol* 1988;76:94-100.
- 369 6. Theisen SK, Podell M, Schneider T, Wilkiw DA, Fenner WR. A retrospective
370 study of cavernous sinus syndrome in 4 dogs and 8 cats. *J Vet Intern Med*
371 1996;10:65-71.
- 372 7. Fransson B, Kippenes H, Silver GE, Gavin PR. Magnetic resonance diagnosis:
373 cavernous sinus syndrome in a dog. *Vet Radiol Ultrasound* 2000;41:536-538.
- 374 8. Larocca RD. Unilateral external and internal ophthalmoplegia caused by
375 intracranial meningioma in a dog. *Vet Ophthalmol* 2000;3:3-9.
- 376 9. Hernández-Guerra AM, López-Múrcia MM, Planells A, Corpa JM, Liste F.
377 Computed tomographic diagnosis of unilateral cavernous sinus syndrome caused
378 by a chondrosarcoma. *Vet J* 2001;174:206-208.
- 379 10. Rossmeisl JHJ, Higgins MA, Inzana KD, Herring IP, Grant DC. Bilateral
380 cavernous sinus syndrome in dogs: 6 cases (1999-2004). *J Am Vet Med Assoc*
381 2005;226:1105-1111.
- 382 11. Webb AA, Cullen CL, Rose P, Eisenbart D, Gabor L, Martinson S. Intracranial
383 meningioma causing internal ophthalmoparesis in a dog. *Vet Ophthalmol*
384 2005;8:421-425.
- 385 12. Grahn BH, Taylor SM, Sandmeyer LS. Diagnostic ophthalmology. *Can Vet J*
386 2007;48:321-322.

- 387 13. Mayhew PD, Bush WW, Glass EN. Trigeminal neuropathy in dogs: a
388 retrospective study of 29 cases (1991–2000). *J Am Anim Hosp Assoc*
389 2002;38:262-270.
- 390 14. Varejao AS, Munoz A, Lorenzo V. (2006) Magnetic resonance imaging of the
391 intratemporal facial nerve in idiopathic facial paralysis in the dog. *Vet Radiol*
392 *Ultrasound* 2006;47:328-333.
- 393 15. Smith PM, Goncalves R, McConnell JF. Sensitivity and specificity of MRI for
394 detecting facial nerve abnormalities in dogs with facial neuropathy. *Vet Rec*
395 2012;171:349-354.
- 396 16. Jeandel A, Thibaud JL, Blot S. Facial and vestibular neuropathy of unknown
397 origin in 16 dogs. *J Small Anim Pract* 2016;57:74-78.
- 398 17. Kern TJ, Erb HN. Facial neuropathy in dogs and cats: 95 cases (1975–1985). *J*
399 *Am Vet Med Assoc* 1987;191:1604–1609.
- 400 18. Jaggy A, Oliver JE, Fergusson DC, Mahaffey EA, Glaus TJ. Neurological
401 manifestations of hypothyroidism: a retrospective study of 29 dogs. *J Vet Intern*
402 *Med* 1994;8:328–336.
- 403 19. Vitale CL, Olby NJ. Neurologic dysfunction in hypothyroid, hyperlipidemic
404 labrador retrievers. *J Vet Intern Med* 2007;21:1316-1322.
- 405 20. Rossmeisl JHJ. Resistance of the peripheral nervous system to the effects of
406 chronic canine hypothyroidism. *J Vet Intern Med* 2010;24:875–881.
- 407 21. Schultz RM, Tucker RL, Gavin PR, Bagley R, Saveraid TC, Berry CR. Magnetic
408 resonance imaging of acquired trigeminal nerve disorders in six dogs. *Vet Radiol*
409 *Ultrasound* 2007;48:101–104.

- 410 22. Motta L, Altay UM, Skerritt GC. Bell's palsy with concomitant idiopathic cranial
411 nerve polyneuropathy in seven dogs. *J Small Anim Pract* 2011;52:397.
- 412 23. Parry AT, Volk HA. Imaging the cranial nerves. *Vet Rad Ultrasound*
413 2011;52:S32-S41.
- 414 24. Seruca C, Rodenas S, Leiva M, Peña T, Añor S. Acute postretinal blindness:
415 ophthalmic, neurologic and magnetic imaging findings in dogs and cats (seven
416 cases). *Vet Ophthalmol* 2010;13:307-314.
- 417 25. Saremi F, Helmy M, Farzin S, Zee CS, Go JL. MRI of cranial nerve enhancement.
418 *Am J Roentgenology* 2005;6:1487-1497.
- 419

420

421 **Appendices**

422 Appendix 1. Clinical Findings for Dogs with Ophthalmoplegia/ophthalmoparesis and

423 Presumed Idiopathic Oculomotor Neuropathy.

Case	Signalment (Breed age sex)	Duration clinical signs (days)	Side of clinical signs	Parasympathetic component CNIII	Motor component CNIII	CSF nucleated cell count (cells/ μ L)	CSF total protein (g/L)
1	Gh 10y MN	5	Left	Plegia	Not affected	0	0.24
2	BC 8y FN	7	Right	Plegia	Not affected	Not available	Not available
3	BT 4y FN	30	Right	Plegia	Not affected	1	0.25
4	Bx 5y ME	5	Right	Paresis	Paresis	0	0.25
5	RC 5y MN	5	Right	Paresis	Paresis	0	0.19
6	Bx 3y FE	4	Right	Plegia	Paresis	8	0.24
7	Bx 7y FN	14	Left	Plegia	Paresis	6	0.24
8	LR 4y FN	180	Left	Plegia	Paresis	1	0.27
9	Bx 8y FN	4	Right	Plegia	Paresis	1	0.31
10	GR 7y MN	1	Left	Plegia	Paresis	0.9	0.22
11	Be 6y MN	30	Right	Plegia	Paresis	4	0.32
12	SBT 9.5y ME	2	Left	Plegia	Paresis	0	0.28
13	BC 7y FN	30/730*	Right	Plegia	Plegia	4	0.35
14	We 3.5y FN	5	Left	Plegia	Plegia	0	0.80

424

425 *Footnote:* Be, Beagle; BC, Border Collie; BT, Border Terrier; Bx, Boxer; CNIII, third

426 cranial nerve; CSF, cerebrospinal fluid; FE, female entire; FN, female neutered; Gh,

427 Greyhound; GR, Golden Retriever; LR, Labrador Retriever; ME, male entire; MN, male

428 neutered; RC, Rough Collie; SBT, Staffordshire Bull Terrier; We, Weimaraner.

429 *, in Case 13 the mydriasis was noted a month prior to presentation and the

430 neuromuscular strabismus two years before.

431

432

433

434 Appendix 2. Magnetic Resonance Findings for Dogs with
435 Ophthalmoplegia/ophthalmoparesis Associated with Presumed Idiopathic Oculomotor
436 Neuropathy.

437

Case	Side of MRI findings	Enlargement			Intensity of CNIII in			Degree of contrast enhancement	Appearance of contrast enhancement	Anatomical area of the lesion
		CNIII	T2W	FLAIR	T1W	T2W	FLAIR			
1	Left	Marked	Hyper	Hyper	Iso	Marked	Diffuse and heterogeneous	MCF		
2	Right	Equivocal	Iso	Iso	No enhancement	MCF				
3	Right	Mild	Iso	Iso	Mild	Focal and homogeneous	MCF			
4	Right	Marked	Hyper	Iso	Marked	Diffuse and heterogeneous	OF and MCF			
5	Right	Equivocal	Hyper	N/A	Mild	Focal and homogeneous	MCF			
6	Right	Mild	Hyper	Hyper	Mild	Focal and homogeneous	MCF			
7	Left	Mild	Hyper	Hyper	Mild	Focal and heterogeneous	MCF			
8	Left	Marked	Hypo	Hypo	Marked	Focal and homogeneous	MCF			
9	Right	Marked	Hyper	N/A	Marked	Focal and heterogeneous	MCF			
10	Left	Equivocal	Iso	Iso	No enhancement	MCF				
11	Right	Marked	Iso	Hypo	Marked	Focal and homogeneous	MCF			
12	Left	Mild	Hyper	Hyper	Mild	Diffuse and homogenous	OF and MCF			
13	Right	Mild	Hypo	Hypo	Mild	Focal and homogeneous	MCF			
14	Left	Marked	Iso	Hypo	Marked	Diffuse and homogeneous	OF and MCF			

438

439 *Footnote:* CNIII, third cranial nerve (oculomotor nerve); Hyper, hyperintensive; Hypo,

440 hypointensive; Iso, isointense; MCF, middle cranial fossa; MRI, magnetic resonance

441 imaging; N/A, not available; OF, orbital fissure.

442

443

444

445 Appendix 3. Treatment, Progression and Follow-up for Dogs with

446 Ophthalmoplegia/ophthalmoparesis Associated with Idiopathic Oculomotor Neuropathy.

447

Case	Systemic corticosteroid treatment	Progression clinical signs during the FU period (CNIII motor and parasympathetic components)	Long term FU (months)	Reason for lost FU
1	No	Unchanged	24	Lost to FU
2	No	Unchanged	77	End of study
3	Prednisolone 1 mg/kg BID for 3w then taping down	Unchanged	39	End of study
4	Prednisolone 1 mg/kg BID for 3w then taping down	Motor and parasympathetic components at 1w post referral	18	Lost to FU
5	No	Unchanged	24	Lost to FU
6	No	Motor and parasympathetic components at 3w post referral	84	Death for unrelated reasons
7	No	Motor component at 3w post referral	42	Death for unrelated reasons
8	No	Unchanged	26	Lost to FU
9	Prednisolone 1 mg/kg SID for 2w then taping down	Motor component at 4m post referral (already off treatment)	41	Death for unrelated reasons
10	Prednisolone 1 mg/kg SID for 1w then discontinue	Motor component at 1m post referral (already off treatment)	20	End of study
11	Prednisolone 1 mg/kg BID for 2w then taping down	Unchanged	20	End of study
12	No	Motor component at 2w post referral	12	End of study
13	Prednisolone 1 mg/kg SID for 1m then taping down	Unchanged	18	Death for unrelated reasons
14	Prednisolone 1 mg/kg SID for 1m then taping down	Motor and parasympathetic components at 1m post referral	30	End of study

448 *Footnote:* CNIII, third cranial nerve (oculomotor nerve); FU, follow-up; MRI, magnetic
449 resonance imaging.

450

451

452

453 **Figure legends**

454




455

456

457 Figure 1. Mydriasis secondary to internal ophthalmoplegia, and upper eyelid ptosis and
458 neuromuscular strabismus (dorsolateral) secondary to external ophthalmoparesis of the
459 left eye in a nine and a half-year-old male entire Staffordshire Bull Terrier (Case 12).


460



461


462

463 Figure 2. Transverse magnetic resonance images obtained at the level of the pituitary
464 gland (asterisk) in a seven-year-old male neutered Golden Retriever presented with
465 internal ophthalmoplegia and external ophthalmoparesis of the left eye (Case 10). There
466 is equivocal enlargement and isointensity of the left oculomotor nerve on T2W (A), on
467 FLAIR (B), and on T1W pre-contrast (C) with no enhancement of left oculomotor
468 following contrast administration (D).



469


470 Figure 3. Transverse magnetic resonance images obtained at the level of the pituitary
471 gland (asterisk) in a seven-year-old female neutered Boxer presented with internal
472 ophthalmoplegia and external ophthalmoparesis of the left eye (Case 7). There is mild
473 enlargement of the left oculomotor nerve with hyperintensity on T2W (arrow; A),
474 hyperintensity on FLAIR (arrow; B), and isointensity on T1W pre-contrast (arrow; C)
475 with mild focal heterogeneous enhancement following contrast administration (arrow; D).



476

477 Figure 4. Transverse magnetic resonance images obtained at the level of the pituitary
478 gland (asterisk) in a six-year-old male neutered Beagle presented with internal
479 ophthalmoplegia and external ophthalmoparesis of the right eye (Case 11). There is
480 marked enlargement of the right oculomotor nerve with isointensity on T2W (arrow; A),
481 hypointensity on FLAIR (arrow; B), and isointensity on T1W pre-contrast (arrow; C)
482 with marked focal homogeneous enhancement following contrast administration (arrow;
483 D).

484



485

486 Figure 5. Transverse magnetic resonance images obtained at the level of the head of the
487 caudate nucleus (asterisk) in a three and a half-year-old female neutered Weimaraner
488 presented with internal ophthalmoplegia and external ophthalmoparesis of the left eye
489 (Case 14). There is marked enlargement of the left oculomotor nerve with isointensity on
490 T2W (arrow; A) and isointensity on T1W pre-contrast (arrow; B), with marked diffuse
491 homogeneous enhancement following contrast administration (arrow; C) at presentation.
492 At six-month follow-up scan, there is resolution of the magnetic resonance findings (D-F).
493